159 related articles for article (PubMed ID: 36472588)
1. Cxcr3 constrains pancreatic cancer dissemination through instructing T cell fate.
Burrack AL; Spartz EJ; Rollins MR; Miller EA; Firulyova M; Cruz E; Goldberg MF; Wang IX; Nanda H; Shen S; Zaitsev K; Stromnes IM
Cancer Immunol Immunother; 2023 Jun; 72(6):1461-1478. PubMed ID: 36472588
[TBL] [Abstract][Full Text] [Related]
2. Distinct myeloid antigen-presenting cells dictate differential fates of tumor-specific CD8+ T cells in pancreatic cancer.
Burrack AL; Schmiechen ZC; Patterson MT; Miller EA; Spartz EJ; Rollins MR; Raynor JF; Mitchell JS; Kaisho T; Fife BT; Stromnes IM
JCI Insight; 2022 Apr; 7(7):. PubMed ID: 35393950
[TBL] [Abstract][Full Text] [Related]
3. B cell-Derived IL35 Drives STAT3-Dependent CD8
Mirlekar B; Michaud D; Lee SJ; Kren NP; Harris C; Greene K; Goldman EC; Gupta GP; Fields RC; Hawkins WG; DeNardo DG; Rashid NU; Yeh JJ; McRee AJ; Vincent BG; Vignali DAA; Pylayeva-Gupta Y
Cancer Immunol Res; 2020 Mar; 8(3):292-308. PubMed ID: 32024640
[TBL] [Abstract][Full Text] [Related]
4. CD40 Agonist Overcomes T Cell Exhaustion Induced by Chronic Myeloid Cell IL-27 Production in a Pancreatic Cancer Preclinical Model.
Burrack AL; Rollins MR; Spartz EJ; Mesojednik TD; Schmiechen ZC; Raynor JF; Wang IX; Kedl RM; Stromnes IM
J Immunol; 2021 Mar; 206(6):1372-1384. PubMed ID: 33558374
[TBL] [Abstract][Full Text] [Related]
5. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
[TBL] [Abstract][Full Text] [Related]
6. STING Activated Tumor-Intrinsic Type I Interferon Signaling Promotes CXCR3 Dependent Antitumor Immunity in Pancreatic Cancer.
Vonderhaar EP; Barnekow NS; McAllister D; McOlash L; Eid MA; Riese MJ; Tarakanova VL; Johnson BD; Dwinell MB
Cell Mol Gastroenterol Hepatol; 2021; 12(1):41-58. PubMed ID: 33548597
[TBL] [Abstract][Full Text] [Related]
7. Radiotherapy enhances CXCR3
Wang CL; Ho AS; Chang CC; Sie ZL; Peng CL; Chang J; Cheng CC
Cancer Immunol Immunother; 2023 Jun; 72(6):1865-1880. PubMed ID: 36688994
[TBL] [Abstract][Full Text] [Related]
8. Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma.
Burrack AL; Spartz EJ; Raynor JF; Wang I; Olson M; Stromnes IM
Cell Rep; 2019 Aug; 28(8):2140-2155.e6. PubMed ID: 31433988
[TBL] [Abstract][Full Text] [Related]
9. Tumor-specific CD4 T cells instruct monocyte fate in pancreatic ductal adenocarcinoma.
Patterson MT; Burrack AL; Xu Y; Hickok GH; Schmiechen ZC; Becker S; Cruz-Hinojoza E; Schrank PR; Kennedy AE; Firulyova MM; Miller EA; Zaitsev K; Williams JW; Stromnes IM
Cell Rep; 2023 Jul; 42(7):112732. PubMed ID: 37402168
[TBL] [Abstract][Full Text] [Related]
10. Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma.
Stromnes IM; Burrack AL; Hulbert A; Bonson P; Black C; Brockenbrough JS; Raynor JF; Spartz EJ; Pierce RH; Greenberg PD; Hingorani SR
Cancer Immunol Res; 2019 Jun; 7(6):977-989. PubMed ID: 31028033
[TBL] [Abstract][Full Text] [Related]
11. CXCL10 and CCL21 Promote Migration of Pancreatic Cancer Cells Toward Sensory Neurons and Neural Remodeling in Tumors in Mice, Associated With Pain in Patients.
Hirth M; Gandla J; Höper C; Gaida MM; Agarwal N; Simonetti M; Demir A; Xie Y; Weiss C; Michalski CW; Hackert T; Ebert MP; Kuner R
Gastroenterology; 2020 Aug; 159(2):665-681.e13. PubMed ID: 32330476
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8
Eissa IR; Mukoyama N; Abdelmoneim M; Naoe Y; Matsumura S; Bustos-Villalobos I; Ichinose T; Miyajima N; Morimoto D; Tanaka M; Fujimoto Y; Sone M; Kodera Y; Kasuya H
Int J Cancer; 2021 Jul; 149(1):214-227. PubMed ID: 33687756
[TBL] [Abstract][Full Text] [Related]
13. The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis.
Hensbergen PJ; Wijnands PG; Schreurs MW; Scheper RJ; Willemze R; Tensen CP
J Immunother; 2005; 28(4):343-51. PubMed ID: 16000952
[TBL] [Abstract][Full Text] [Related]
14. T-cell programming in pancreatic adenocarcinoma: a review.
Seo YD; Pillarisetty VG
Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
[TBL] [Abstract][Full Text] [Related]
15. Th17 cells inhibit CD8
Wang D; Yu W; Lian J; Wu Q; Liu S; Yang L; Li F; Huang L; Chen X; Zhang Z; Li A; Liu J; Sun Z; Wang J; Yuan W; Zhang Y
J Hematol Oncol; 2020 Jun; 13(1):68. PubMed ID: 32503584
[TBL] [Abstract][Full Text] [Related]
16. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
17. Insufficiency of compound immune checkpoint blockade to overcome engineered T cell exhaustion in pancreatic cancer.
Stromnes IM; Hulbert A; Rollins MR; Basom RS; Delrow J; Bonson P; Burrack AL; Hingorani SR; Greenberg PD
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35210305
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral Plasmid IL12 Expands CD8
Telli ML; Nagata H; Wapnir I; Acharya CR; Zablotsky K; Fox BA; Bifulco CB; Jensen SM; Ballesteros-Merino C; Le MH; Pierce RH; Browning E; Hermiz R; Svenson L; Bannavong D; Jaffe K; Sell J; Foerter KM; Canton DA; Twitty CG; Osada T; Lyerly HK; Crosby EJ
Clin Cancer Res; 2021 May; 27(9):2481-2493. PubMed ID: 33593880
[TBL] [Abstract][Full Text] [Related]
19. CXCR3 and Cognate Ligands are Associated with Immune Cell Alteration and Aggressiveness of Pancreatic Ductal Adenocarcinoma.
Cannon A; Thompson CM; Maurer HC; Atri P; Bhatia R; West S; Ghersi D; Olive KP; Kumar S; Batra SK
Clin Cancer Res; 2020 Nov; 26(22):6051-6063. PubMed ID: 32873571
[TBL] [Abstract][Full Text] [Related]
20. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
Muth ST; Saung MT; Blair AB; Henderson MG; Thomas DL; Zheng L
Cancer Lett; 2021 Feb; 499():99-108. PubMed ID: 33271264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
